MAPT and frontotemporal dementia: Notably, this panel was previously used in human patients with frontotemporal lobar degeneration with tau pathology (FTLD-tau), which revealed significant glial dysregulation in FTLD-tau compared to controls, including alterations in multiple astrocyte-, microglia-, and oligodendrocyte-related pathways (Ferrer et al., 2014).